HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.
Hanssen Pharma (03692) announced that its self-developed class 1 new drug HS-10582 tablets have received the clinical trial approval notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."
HANSOH PHARMA (03692) announced that its self-developed Class 1 new drug HS-10582 tablets have received a clinical trial approval notification from the National Medical Products Administration (NMPA) in China, aimed at conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."
Related Articles
Why has the core product behind faced commercialization obstacles in the US, and how did the stock price of ACOTEC-B (06669) plunge before reversing?
Yushujing Technology (688836.SH) IPO Heat and the Noise: The Dark Pool Trading Rumors Are Groundless, and the Risks Behind Should Not Be Underestimated.
DAMAI ENT (01060) launches the "Good Luck Continuous" brand's plan for eight stores in six cities.
Why has the core product behind faced commercialization obstacles in the US, and how did the stock price of ACOTEC-B (06669) plunge before reversing?
Yushujing Technology (688836.SH) IPO Heat and the Noise: The Dark Pool Trading Rumors Are Groundless, and the Risks Behind Should Not Be Underestimated.
DAMAI ENT (01060) launches the "Good Luck Continuous" brand's plan for eight stores in six cities.
RECOMMEND
